TASK Brooklyn

Primary Focus

TASK Brooklyn’s primary role is to conduct clinical research trials into effective treatment for Multi-Drug Resistant TB (MDR-TB) and Extremely Drug Resistant TB (XDR-TB)

TASK Brooklyn Chest – Phase 2 & 3 Clinical Trial Site

TASK Brooklyn’s historic role was to conduct clinical research trials into effective treatment for Multi-Drug Resistant TB (MDR-TB) and Extremely Drug Resistant TB (XDR-TB)

Clinic specifications

  • a 25 bed in-patient capacity and is based within the grounds of Brooklyn Chest Hospital (a state managed facility) which enables access to specialized hospital services, namely:
    • Radiography
    • Audiology
    • Occupational Therapy
    • Physiotherapy
    • Dietetics
    • Social work
  • Infection and ventilated controlled participant wards via negative air pressure.
  • On site sample processing room with centrifuge and refrigeration
  • Restricted areas for infectious disease control
  • Central time monitored for IP protocol adherence
  • Onsite nursing staff that are equipped and skilled in managing medical emergencies (emergency trolleys installed)
  • CCTV monitored, access-controlled and on site, off street secure parking
  • In-house pharmacy registered with the South African Pharmacy Council and South African Department of Health (DOH) as an institutional pharmacy for clinical trials
  • On-site support team offices including monitor offices, reception areas, doctors rooms
  • Back-up generators on site and other electrical redundancies installed
  • Dedicated participant transport
  • Experienced and GCP trained DOT (directly observed therapy) staff who go out to see study participants and work with them in their home environment to support them during their treatment

Supported by

  • Dedicated team of trial recruiters based at Department Of Health and City of Cape Town clinics.
  • TASK HQ comprising of a quality and regulatory team; data management centre; finance and admin team and BSL3 Laboratory

Accredited by

    • Aids Clinical Trial Group (ACTG) approved
    • Federal Drug Administration (FDA) and European Medicines Agency (EMA) inspected

 

Site Coordinator

  • Michelle Eriksson
  • 021 510 2207
  • Stanberry Road,

    Ysterplaat,

    7405